IRB #

STUDY00023443

Title

ASCEND 2: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

Principal Investigator

Tom Beer

Study Purpose

The primary purpose of this study is to get blood specimens from cancer subjects and healthy subjects (no cancer) to develop and improve tests for cancer in the blood.

Medical Condition(s)

Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Bladder Cancer, Uterine Cancer, Kidney/Renal Pelvic Cancer, Pancreatic Cancer, Liver Cancer, Stomach Cancer, Ovarian Cancer, Esophageal Cancer, Head and Neck Squamous Cell Cancer, Thyroid Cancer, Small Intestine Cancer, Anal Cancer, Cervical Cancer, Vulva Cancer, Testicular Cancer.

Eligibility Criteria

1. 50 years of age or greater.
2. Able to understand study procedures and provide informed consent.
3. Should meet one of the following at time of enrollment:
a) Individual with no history of cancer.
b) Individual with untreated primary cancer of the following confirmed through pathology/radiology reports reports and/or clinical data: Breast, Lung, Colorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvic, Pancreatic, Liver, Stomach, Ovarian, Esophageal, Head and Neck Squamous Cell, Thyroid, Small Intestine, Anal, Cervical, Vulva, Testicular.
c) Individual suspected to have a primary malignancy of Pancreatic Cancer, Bladder Cancer, Kidney/Renal Pelvic Cancer, Testicular Cancer, or Ovarian Cancer based on imaging.

Age Range

50 - N/A

Healthy Volunteers Needed

Yes

Duration of Participation

The study will have 1 visit. Duration of visit for each participant will be about 30 minutes to go over eligibility, medical history, and blood sample collection. Study participation is complete upon successful blood draw, no follow-up period expected.

Minors Included

No

Contact

cedartrials@ohsu.edu
503-418-8150

Sponsor

Exact Sciences Thrive LLC

Recruitment End

08/17/2026

Compensation Provided

Yes

Compensation

One-time $50 compensation for participation given after a complete blood draw.


Go Back